CHANGES OF OXIDATIVE MODIFICATION OF PROTEINS AND ANTIOXIDANT ACTIVITY IN THE BLOOD OF DIFFERENT SEXES RATS WITH STEATOGEPATOSIS AND THEIR CORRECTION WITH MYO-INOSITOL
DOI:
https://doi.org/10.11603/mcch.2410-681X.2023.i4.14373Keywords:
oxidatively modified proteins, antioxidant activity, inositol, steatohepatosis, rats, sexAbstract
Introduction. Liver disease, in particular steatohepatosis, is one of the main problems today, which is complicated by cardiovascular, neurological, and renal diseases. One of the methods of correcting liver damage can be the use of inositol.
The aim of the study – to evaluate changes in oxidatively modified proteins and antioxidant activity in the blood of rats with steatohepatosis and to carry out correction with myo-inositol.
Research Methods. Experiments were performed on 80 white male and female Wistar rats. The animals were divided into 4 groups: 1 – control, 2 – steatohepatosis, 3 – myo-inositol, 4 – steatohepatosis + correction with myo-inositol. Steatohepatosis was induced by giving 5 % glucose solution instead of drinking for 2 months. Myo-inositol powder was added to animals' food (porridge) for 60 days at the rate of 400 mg/kg of animal weight as inositol after simulating steatohepatosis. The content of oxidatively modified proteins (OMP) at wavelengths of 370 nm and 430 nm and superoxide dismutase and catalase activity (SOD, Cat) were determined in blood serum.
Results and Discussion. In the 2nd group of males and females, OMP increased significantly. In animals of group 3, compared to group 1, OMPs increased, but were smaller compared to group 2. In rats of the 4 groups the OMP was higher compared to the 1 group, but smaller compared to the 2 group and larger compared to the 3 group. In all periods of observation, OMP values were lower in females compared to males: OMP370 in 1 group of males was higher by 26.9 % (p<0.001), in 2 by 21.1 % (p<0.001), in 3 by 52.2 % (p<0.001), in 4 – by 25.0 % (p<0.001); OMP430 in 1 group of males was higher by 39.3 % (p<0.001), in 2 by 23.4 % (p<0.001), in 3 by 56.6 % (p<0.001), in 4 by 23.6 % (p<0.001). SOD in males of group 2, compared to group 1, decreased by 14.4 % (p<0.001), Cat – by 14.1 % (p<0.001). In males of group 3, compared to 1, SOD increased by 17.9 % (p<0.001), and was greater, compared to group 2, by 37.8 % (p<0.001); Cat was greater, compared to group 1, by 18.0 % (p<0.001), and compared to group 2 – by 37.3 % (p<0.001). In group 4, SOD was smaller, compared to group 3, by 18.1 % (p<0.001); Cat – by 24.5 % (p<0.001). SOD in females of group 2, compared to group 1, decreased by 13.4% (p<0.001), Cat – by 13.8 % (p<0.001). In females of group 3, SOD was greater, compared to group 2, by 19.2 % (p<0.001); Cat – by 22.0% (p<0.001). In group 4, SOD was greater, compared to group 2, by 12.8 % (p<0.001), Cat – by 18.0 % (p<0.001). Only in group 3, Cat was lower in females, compared to males, by 19.2 % (p<0.001).
Conclusion. Steatohepatosis in rats causes an increase in oxidatively modified proteins, a decrease in superoxide dismutase and catalase activity. Myo-inositol at a dose of 400 mg/kg causes accumulation of oxidatively modified proteins regardless of sex and significant activation of antioxidants in the blood of male rats. In the treatment of steatohepatosis, myo-inositol at a dose of 400 mg/kg, with the normalization of eating habits, causes significantly less accumulation of oxidatively modified proteins.
References
Younossi, Z., Anstee, Q.M., Marietti, M., Hardy, T., Henry, L., Eslam, M., et al. (2018). Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol., 15. https://doi.org/10.3390/nu12113379.
Pani, A., Giossi, R., Menichelli, D., Fittipaldo, V.A., Agnelli, F., Inglese, E., et al. (2020). Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients, 12(11). https://doi.org/10.3390/nu12113379.
Baratta, F., Pastori, D., Angelico, F., Balla, A., Paganini, A.M., Cocomello, N., et al. (2020). Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 18. https://doi.org/10.1016/j.cgh. 2019.12.026
Anstee, Q.M., Mantovani, A., Tilg, H., & Targher, G. (2018). Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol., 15. https://doi.org/10.1038/s41575-018-0010-0.
Kiani, A.K., Paolacci, S., Calogero, A.E., Cannarella, R., Di Renzo, G.C., Gerli, S., et al. (2021). From Myo-inositol to D-chiro-inositol molecular pathways. Eur. Rev. Med. Pharmacol. Sci., 25(5). https://doi.org/10.26355/eurrev_202103_25279.
Yuzko, O. M. (2021). Reproductive health of parents: Review of the literature. Reproductive endocrinology, (60). https://doi.org/10.18370/2309-4117. 2021.60.72-76 [in Ukrainian].
Kulik, I.I., & Khmil, S.V. (2020). The effect of sclerotherapy and pre-pregnancy training with inositol and vitamin D3 on the size and number of cysts in women with infertility on the background of endometriosis. Reports of Vinnytsia National Medical University, 24 (3). https://doi.org/10.31393/reports-vnmedical-2020-24(3)-12 [in Ukrainian].
Kostiuk, O. A., Denefil, O.V., & Holovata, T.K. (2018). Changes in biochemical parameters in the blood of high- and low-emotional rats with ethanol hepatosis. Medical and Clinical Chemistry. 20 (3). https://doi.org/10.11603/mcch.2410-681X.2018.v0.i3.9578 [in Ukrainian].
Bevilacqua, A., Dragotto, J., Giuliani, A., Bizzarri, M. (2019). Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J. Cell Physiol., 234. https://doi.org/10.1002/jcp.27623
Vlizlo, V.V. (Ed.). (2012). Laboratory methods of research in biology, animal husbandry and veterinary medicine: reference book. Lviv: SPOLOM [in Ukrainian].
Meshchyshyn, І.F. (1998). Method for deter-mination of oxidative protein modification of blood plasma (serum) proteins. Bukovyna Medical Herald, 2 (1) [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
